Výsledky vyhledávání - "Jasmin Greinemann"

Abstract P5-19-11: Noninterventional study HELENA – Advanced (metastatic or locally recurrent, inoperable) HER2-positive breast cancer: First-Line trEatmeNt with pertuzumAb after adjuvant trastuzumab therapy

Autor: Marc Thill, Katja Ziegler-Löhr, Jasmin Greinemann, Harald Wagner, Dietmar Reichert, Gertrud Helling-Giese, Otto Schmalhofer

Publikováno v: Cancer Research. 75:P5-19

Background: The CLEOPATRA trial (808 patients) demonstrated a significant benefit for overall survival (HR=0.66; 95% CI 0.52−0.84; p Methods & Aims: HELENA is a multicentre, noninterventional study recruiting patients with advanced HER2-positive br

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8d6abd73a84ce6acecd27b9af47e135c
https://doi.org/10.1158/1538-7445.sabcs14-p5-19-11

Zobrazit plný text záznamu

Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2 therapy

Autor: Dietmar Reichert, Carsten Hielscher, Thomas Hitschold, Frank Gerhard Foerster, Jan Janssen, David Julian Borquez, Marcus Schmidt, Jan Schroeder, Tobias Hesse, Lars Hanker, Andrea Grafe, Jasmin Greinemann

Publikováno v: Journal of Clinical Oncology. 31:602-602

602 Background: Addition of trastuzumab (Roche; T) to chemotherapy (CT) has improved outcomes in patients (pts) with HER2+ breast cancer at all stages, including locally advanced and metastatic disease. Anti-HER2 re-treatment with T is an increasingl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0e7d45aacb703e760919ed7f4662f9ca
https://doi.org/10.1200/jco.2013.31.15_suppl.602

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání